Previous studies have also shown increased NR2F6 expression in leukemia patients [10], breast cancer with poor prognosis [25], cervical cancer with pelvic lymph node metastasis and poor prognosis [7], and chemotherapy-resistant ovarian cancer [5]. This evidence concerns the gene NR2F6 and ovarian carcinoma.